24 May 2013
Keywords: biogen, idec, co-develop, cardiokine, lixivaptan, drugmakers, signed
Article | 09 July 2007
US drugmakers Biogen Idec and Cardiokine have signed an agreement to jointly develop lixivaptan, an oral compound expected to enter ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 July 2007
© 2013 thepharmaletter.com